Human whole saliva is readily accessible and noninvasive. The authors reported saliva can reflect both systemic and oral physiology, offering a potential substitute for venipuncture where pre-analytical vulnerabilities such as ex vivo glycolysis compromise blood testing. The review positions saliva not as a universal replacement but as a complementary matrix with practical advantages for repeat sampling, remote collection, and reduced procedural risk.
The paper noted several clinical contexts where saliva has been explored: glycemic monitoring, cardiovascular risk assessment, infectious disease screening, critical care surveillance, endocrine testing, oncology liquid biopsy, and neurodegenerative biomarker research. The authors did not provide standardized clinical cutoffs or detailed sensitivity/specificity figures; they emphasized that many measures remain exploratory and require prospective validation.
Investigators cataloged candidate analytes by specialty. For glycemic control, the review lists salivary glucose, 1,5-anhydroglucitol, and α2-macroglobulin. Cardiology-focused markers include salivary cardiac troponin I (cTnI), high-sensitivity C-reactive protein (hs-CRP), and salivary alpha-amylase (sAA). The critical care and sepsis section highlights inflammatory mediators such as IL-10 and a range of acute-phase proteins measured in oral fluid.
Endocrinology applications referenced free steroid hormones in saliva as measures of biologically active fractions. For infectious diseases, the authors reviewed salivary testing for HIV, HCV, and SARS-CoV-2, noting both antibody and molecular detection formats have been evaluated. Oncology discussions centered on exosomal microRNAs and ctDNA isolated from saliva as a noninvasive liquid biopsy source. In neurology, candidate biomarkers included Aβ42, phosphorylated tau (p-tau181), and lactoferrin, which investigators have measured in saliva for Alzheimer’s-related research. The review did not report uniform reference intervals across these analytes and cautioned against overinterpretation of preliminary correlations without prospective validation.
The authors described a spectrum of assay technologies. Traditional laboratory methods—high-sensitivity immunoassays and mass spectrometry—remain central to discovery and validation work. On the point-of-care end, wearable electrochemical biosensors and other portable platforms were evaluated for their potential to detect low-abundance analytes in real time.
Regulatory distinctions were drawn between assays already cleared for clinical use and those still at discovery stage. The review identified regulatory-cleared salivary applications, including FDA PMA/510(k), EUA, CE-IVD marked platforms, and SAMHSA-certified panels used for viral antibody testing, late-night salivary cortisol, and certain toxicology assays. The authors noted a larger field of emerging panels that have not yet met the evidence threshold for broad clinical deployment.
Data indicated three recurrent obstacles limiting routine clinical adoption: unstandardized collection protocols, interference from the oral matrix, and the absence of established normal ranges for many analytes. The review team recommended three priorities to address these gaps: implement universal sampling standardization that incorporates flow-rate normalization; engineer matrix-matched biosensors optimized for sub-picomolar detection; and conduct rigorous multicenter prospective trials to validate definitive clinical cutoffs and characterize blood-saliva correlation kinetics.
The authors emphasized that assay sensitivity and sample handling are tightly linked; without harmonized collection procedures, analytical gains will be difficult to translate into reliable clinical decisions.
Several specific unanswered questions remain, as reported by the authors. Multicenter prospective data are lacking to establish validated clinical cutoffs for most salivary analytes. Dynamic correlation kinetics between blood and saliva—how quickly and to what extent concentrations equilibrate—require systematic study before saliva can substitute for blood in acute-care decision making. The review stated that engineering of matrix-matched sensors and clinical trials are necessary steps; it did not provide timelines, trial sizes, or numeric performance metrics for those studies.
Regulatory-cleared salivary tests do exist for a limited set of applications, yet widespread translation will depend on standardized sampling protocols, analytic platforms designed specifically for the oral matrix, and coordinated multicenter validation. Those are the concrete next steps documented by the authors, and they remain prerequisites for routine clinical use rather than speculative recommendations.